Lv21
108 积分 2024-07-24 加入
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
2小时前
已完结
HER2 in gynecological malignancies: Bridging the gap between standardized pathological assessment and precision therapy
7天前
已关闭
[Chinese clinical practice guideline for genetic testing in advanced breast cancer (2025 edition)]
1个月前
已完结
Next-generation sequencing for PTEN testing in HR+/HER2˗ metastatic breast cancer
1个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
1个月前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
2个月前
已完结
[Guideline for HER2 testing in breast cancer (2024 version)]
2个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
4个月前
已完结
Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
4个月前
已完结
皖公网安备34019202002308
